The chronic myeloid leukemia stem cell: stemming the tide of persistence
TL Holyoake, D Vetrie - Blood, The Journal of the American …, 2017 - ashpublications.org
Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …
[HTML][HTML] Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
MM Sampaio, MLC Santos, HS Marques… - World journal of …, 2021 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …
Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy
Y Choi, K Jung - Experimental & Molecular Medicine, 2023 - nature.com
Solid tumors are complex entities that actively shape their microenvironment to create a
supportive environment for their own growth. Angiogenesis and immune suppression are …
supportive environment for their own growth. Angiogenesis and immune suppression are …
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
YD Irani, A Hughes, J Clarson, CH Kok… - British Journal of …, 2020 - Wiley Online Library
There is currently no biomarker that reliably predicts treatment‐free remission (TFR) in
chronic myeloid leukaemia (CML). We characterised effector and suppressor immune …
chronic myeloid leukaemia (CML). We characterised effector and suppressor immune …
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
C Schütz, S Inselmann, S Sausslele, CT Dietz… - Leukemia, 2017 - nature.com
It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains
treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy …
treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy …
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
M Massimino, S Stella, E Tirrò, C Romano, MS Pennisi… - Molecular cancer, 2018 - Springer
The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …
Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation
H Mu, X Zhu, H Jia, L Zhou, H Liu - Frontiers in Oncology, 2021 - frontiersin.org
Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …
[HTML][HTML] Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients
G Caocci, B Martino, M Greco, E Abruzzese… - Experimental …, 2015 - Elsevier
Highlights•The role of NK cells and their receptors on TFR in CML is intriguing•Cumulative
TFR is significantly higher in patients homozygous for KIR A haplotype•KIR3DS1/KIR3DL1 …
TFR is significantly higher in patients homozygous for KIR A haplotype•KIR3DS1/KIR3DL1 …
Immunosuppressive cell subsets and factors in myeloid leukemias
J Swatler, L Turos-Korgul, E Kozlowska, K Piwocka - Cancers, 2021 - mdpi.com
Simple Summary Effector immune system cells have the ability to kill tumor cells. However,
as a cancer (such as leukemia) develops, it inhibits and evades the effector immune …
as a cancer (such as leukemia) develops, it inhibits and evades the effector immune …
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
A Kreutzman, M Ilander, K Porkka, J Vakkila… - …, 2014 - Taylor & Francis
Tyrosine kinase inhibitors (TKIs) have dramatically improved the outcome of chronic myeloid
leukemia (CML). Besides inhibiting target kinases in leukemic cells, 2nd generation TKI …
leukemia (CML). Besides inhibiting target kinases in leukemic cells, 2nd generation TKI …